Categories Breaking News, Health Care
TRxADE Health changes its name to Scienture Holdings
The stock trades on the Nasdaq Stock Market under the new symbol SCNX
Trxade Health, Inc. (NASDAQ: MEDS), a leading health services IT company, and its wholly owned subsidiary Scienture, LLC revealed that Trxade has changed its name to Scienture Holdings, Inc. Now, the stock trades on the Nasdaq Stock Market under the new ticker symbol SCNX.
Scienture Holdings, through its subsidiaries Scienture and Integra Pharma Solutions, operates as a comprehensive pharmaceutical product company, offering specialty products to satisfy unmet market needs. Its products are in development across therapeutic areas and indications, serving different market segments and channels. Scienture Holdings will be led by Suren Ajjarapu, who has been serving Trxade as chief executive officer. Suren is also chairman of the board of directors.
In July this year, Trxade completed its business combination with Scienture in a $103-million deal. Under the all-stock transaction, the company acquired all of Scienture’s assets in exchange for shares of Trxade’s stock.
Scienture, LLC is a New York-based pharmaceutical company with strategic capabilities across R&D, manufacturing, sales & marketing, and commercial operations. Last month, Narasimhan Mani was appointed as Scienture’s president. Rahul Surana was promoted to executive vice president and chief operating officer of the company.
Integra Pharma Solutions is a pharmaceutical supplier with expertise in product distribution across all key healthcare markets including government organizations, hospitals, clinics, and independent pharmacies.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DAL Earnings: All you need to know about Delta Air Lines’ Q1 2025 earnings results
Delta Air Lines (NYSE: DAL) reported its first quarter 2025 earnings results today. Operating revenue increased 2% year-over-year to $14 billion. Net income was $240 million, or $0.37 per share,
Deals and R&D in focus as Johnson & Johnson gears up for Q1 earnings
For Johnson & Johnson (NYSE: JNJ), investments in its pipeline and exiting lower priority businesses remain central to its strategy in the new fiscal year. The healthcare behemoth is in
Earnings preview: What to expect when these major banks report Q1 2025 results
The leading players in the banking industry are set to report their earnings results for the first quarter of 2025 over this week and the next. While majors JPMorgan Chase